title: Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.
abstract: BACKGROUND
  The determination of sensitive chemotherapy drugs for gastric cancer (GC) is one of the greatest challenges of adjuvant therapy. Here we evaluated the chemosensitivity of GC to anticancer drugs and the telomerase reverse transcriptase (hTERT) mRNA expression, and investigated the relationship of them.
  
  
  METHODS
  The GC cells which were collected from 68 patients with primary GC were primary cultured. The chemosensitivity of GC cells to anticancer drugs was evaluated successfully using the MTT assay for 60 cases of GC cells, and the hTERT mRNA expression was examined in 60 cases of GC tissues and corresponding normal gastric mucosa and 6 cases of chronic superficial gastritis mucosa by in situ hybridization.
  
  
  RESULTS
  Taxol, cisplatin and 5-fluorouracil were in general more effective than adriamycin and mitomycin for GC cells, and the chemosensitivity to anticancer drugs was associated with tumor histological types and a worse tumor grade. Compared to normal gastric mucosa tissues, hTERT mRNA expression was significantly increased in GC (P<0.05), which was related with a worse differentiation and drug-resistance to 5-fluorouracil or adriamycin in GC.
  
  
  CONCLUSIONS
  These data demonstrate for the first time that examinations of hTERT mRNA expression as an important factor could be used to select the chemotherapeutic drugs for GC patients.
  The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1793217009875483.
authors: Department of Pathology, General Hospital of Jinan Military Command, Jinan, Shandong Province, China. gm2227@sina.com
authors: Lin
authors: L
authors: Wang
authors: Pei-Feng
authors: PF
authors: Li
authors: Ming
authors: M
authors: Geng
authors: Yong-Cheng
authors: YC
authors: Cao
authors: Ying-Chun
authors: YC
authors: Yin
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D002288:Adenocarcinoma, Mucinous / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000231:Adenocarcinoma, Papillary / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000235:genetics*; D018279:Carcinoma, Signet Ring Cell / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D016022:Case-Control Studies; D002454:Cell Differentiation; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004354:Drug Screening Assays, Antitumor; D005472:Fluorouracil / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017403:In Situ Hybridization; D016685:Mitomycin / Q000494:pharmacology; D060787:Neoplasm Grading; D017239:Paclitaxel / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D019098:Telomerase / Q000235:genetics*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D016685:Mitomycin; D004317:Doxorubicin; C509186:TERT protein, human; D019098:Telomerase; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil